Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

News SummaryMost relevantAll newsSector news 

Mylan Inc. : Before the Bell Scans of MYL, TEVA, COV, VRX, and ZTS

share with twitter share with LinkedIn share with facebook
share via e-mail
05/09/2013 | 08:50am CEST

StockCall.com Provides Stock Research on Mylan Inc., Teva Pharmaceutical Industries Ltd, Covidien plc, Valeant Pharmaceuticals International Inc., and Zoetis Inc.

New York City, New York -- (May 09, 2013)

Equity markets edged higher on Wednesday after struggling initially. It was yet another historic day as the Dow Jones and the S&P 500 closed at fresh all-time high levels. Market sentiment was lifted by better-than-expected trade data from China. Improving global economic outlook coupled with ultra-loose monetary policies from developed world central banks have boosted investors? risk appetite. Yesterday, the healthcare sector was among the best performers in the S&P 500. Among the major movers in this sector were Mylan Inc. (NASDAQ: MYL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Covidien Plc (NYSE: COV), Vertex Pharmaceuticals International Inc. (NYSE: VRX), and Zoetis Inc. (NYSE: ZTS). StockCall has taken an interest in these companies and you can now sign up to download the free technical research on MYL, TEVA, COV, VRX, and ZTS at


Mylan Inc.?s shares edged lower in trading on Wednesday. The stock traded between $29.30 and $29.93 before finishing the day 1.21% lower at $29.33 on volume of 4.41 million. Despite the losses yesterday, Mylan?s shares have gained nearly 1.50% in the last three trading sessions. Year-to-date, the stock has gained more than 6.80%, underperforming the broad market. Shares of MYL are currently trading more than 6% below their 52-week high. Sign up today to read the free research report on MYL at


Shares of Teva Pharmaceutical Industries Ltd. edged higher in yesterday?s trading session; however, the gains were limited. The stock closed 0.18% higher at $38.42 on volume of 2.94 million. Teva Pharmaceutical?s shares are currently trading close to their 52-week low of $38.33. The stock is also trading below its 50-day and 200-day moving averages which is a bearish signal. However, the stock?s MACD has just crossed above the signal line which suggests that market sentiment has turned bearish. Register to download the free technical analysis on TEVA at


Shares of Covidien Plc edged higher on Wednesday, tracking gains in the broad market. The stock touched an intraday high of $65.88 before finishing the day 0.98% higher at $65.88 on volume of 2.89 million. Covidien?s shares have gained nearly 2.40% in the last three trading sessions. The stock has seen a series of highs over the past week which is a bullish signal. The positive trend is further confirmed by recent volume activity, and the stock?s MACD chart. Free report on COV can be accessed by registering at


Valeant Pharmaceuticals International Inc.?s shares struggled in yesterday?s trading session. The stock ended the day 0.28% lower at $73.86 on volume of 713,719. The company?s shares are currently trading close to their 52-week high of $76.57. The stock has gained nearly 23.60% so far in 2013 as compared to a gain of nearly 14.50% for the S&P 500. The stock is currently trading above its 50-day and 200-day moving averages.Register withStockCall and download the research on VRX for free at


Shares of Zoetis Inc. rose in trading on Wednesday. The stock touched an intra-day high of $33.44 before finishing the day 1.16% higher at $33.26 on volume of 1.03 million. Zoetis?shares have underperformed the S&P 500 so far in 2013, gaining nearly 7.50%. The stock?s MACD is currently trading above the signal line and the zero-line which is a bullish signal. Shares of ZTS are trading nearly 6% below their 52-week high. Read the full free research on ZTS by signing up to StockCall at


About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at


Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYLAN INC
02:19a Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 Fr..
10/21 Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in My..
10/20 MYL NOTICE : Rosen Law Firm Reminds Mylan N.V. Investors of Important Deadline i..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/14 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Mylan N.V. In..
10/13 BERNSTEIN LIEBHARD LLP : Announces That A Suit Has Been Filed Against Mylan, N.V..
10/12 Investigation of Mylan N.V. Announced by Law Offices of Howard G. Smith
10/11 Rosen Law Firm Files Securities Class Action Lawsuit Against Mylan N.V. - MYL
10/10DJMARKET SNAPSHOT : U.S. Stocks March Higher As Oil Rally Fuels Energy-sector Gain..
10/10DJU.S. Stocks Gain Amid Rising Oil Prices
More news
Sector news : Pharmaceuticals - NEC
03:25aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
02:36aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24DJGLAXOSMITHKLINE : 3Q 2016 -- Forecast
10/24DJSyngenta and ChemChina Miss EU Deadline for Antitrust Remedies
10/24 GSK files potential $1 billion shingles vaccine for U.S. approval
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Financials ($)
Sales 2016 11 091 M
EBIT 2016 3 157 M
Net income 2016 2 006 M
Debt 2016 10 941 M
Yield 2016 -
P/E ratio 2016 14,47
P/E ratio 2017 9,41
EV / Sales 2016 2,77x
EV / Sales 2017 2,37x
Capitalization 19 802 M
More Financials
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 53,4 $
Spread / Average Target 44%
Consensus details
EPS Revisions
More Estimates Revisions
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%19 802
JOHNSON & JOHNSON10.60%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.46%195 193
MERCK & CO., INC.15.01%169 231
More Results